Works matching IS 15228517 AND DT 2022 AND VI 24 AND IP 6
Results: 24
Radiomic signatures of posterior fossa ependymoma: Molecular subgroups and risk profiles.
- Published in:
- Neuro-Oncology, 2022, v. 24, n. 6, p. 986, doi. 10.1093/neuonc/noab272
- By:
- Publication type:
- Article
Combined immunotherapy with controlled interleukin-12 gene therapy and immune checkpoint blockade in recurrent glioblastoma: An open-label, multi-institutional phase I trial.
- Published in:
- Neuro-Oncology, 2022, v. 24, n. 6, p. 951, doi. 10.1093/neuonc/noab271
- By:
- Publication type:
- Article
Phase II trial of response-based radiation therapy for patients with localized germinoma: a Children's Oncology Group study.
- Published in:
- Neuro-Oncology, 2022, v. 24, n. 6, p. 974, doi. 10.1093/neuonc/noab270
- By:
- Publication type:
- Article
Decade-long disease, secondary malignancy, and brainstem injury outcomes in pediatric and young adult medulloblastoma patients treated with proton radiotherapy.
- Published in:
- Neuro-Oncology, 2022, v. 24, n. 6, p. 1010, doi. 10.1093/neuonc/noab257
- By:
- Publication type:
- Article
Human embryonic stem cell-derived neural crest model unveils CD55 as a cancer stem cell regulator for therapeutic targeting in MYCN-amplified neuroblastoma.
- Published in:
- Neuro-Oncology, 2022, v. 24, n. 6, p. 872, doi. 10.1093/neuonc/noab241
- By:
- Publication type:
- Article
Forthcoming Meetings.
- Published in:
- Neuro-Oncology, 2022, v. 24, n. 6, p. 1034, doi. 10.1093/neuonc/noac129
- Publication type:
- Article
Pediatric ependymoma: New perspectives on older trials.
- Published in:
- Neuro-Oncology, 2022, v. 24, n. 6, p. 949, doi. 10.1093/neuonc/noac060
- By:
- Publication type:
- Article
Loss of ATRX suppresses anti-tumor immunity.
- Published in:
- 2022
- By:
- Publication type:
- Editorial
Bioethical implications of current state practices of molecular diagnostics in neuropathology.
- Published in:
- Neuro-Oncology, 2022, v. 24, n. 6, p. 853, doi. 10.1093/neuonc/noac058
- By:
- Publication type:
- Article
TRK inhibition for pediatric and adult central nervous system tumors: Early promise and future questions.
- Published in:
- Neuro-Oncology, 2022, v. 24, n. 6, p. 1008, doi. 10.1093/neuonc/noac048
- By:
- Publication type:
- Article
Chemotherapy plus focal radiation therapy for localized intracranial germinoma: How little is enough?
- Published in:
- Neuro-Oncology, 2022, v. 24, n. 6, p. 984, doi. 10.1093/neuonc/noac047
- By:
- Publication type:
- Article
Radiomics—A new age of presurgical assessment to improve outcomes in pediatric neuro-oncology.
- Published in:
- Neuro-Oncology, 2022, v. 24, n. 6, p. 995, doi. 10.1093/neuonc/noac046
- By:
- Publication type:
- Article
Standardizing reporting of brain and central nervous system tumors in the United Kingdom.
- Published in:
- Neuro-Oncology, 2022, v. 24, n. 6, p. 1032, doi. 10.1093/neuonc/noac027
- By:
- Publication type:
- Article
Two clinically distinct cases of infant hemispheric glioma carrying ZCCHC8:ROS1 fusion and responding to entrectinib.
- Published in:
- 2022
- By:
- Publication type:
- Case Study
CD55, a potential immunotherapeutic target for MYCN-amplified neuroblastoma.
- Published in:
- Neuro-Oncology, 2022, v. 24, n. 6, p. 886, doi. 10.1093/neuonc/noac020
- By:
- Publication type:
- Article
SIOP Ependymoma I: Final results, long-term follow-up, and molecular analysis of the trial cohort—A BIOMECA Consortium Study.
- Published in:
- Neuro-Oncology, 2022, v. 24, n. 6, p. 936, doi. 10.1093/neuonc/noac012
- By:
- Publication type:
- Article
Liquid biopsy in gliomas: A RANO review and proposals for clinical applications.
- Published in:
- Neuro-Oncology, 2022, v. 24, n. 6, p. 855, doi. 10.1093/neuonc/noac004
- By:
- Publication type:
- Article
ATRX loss promotes immunosuppressive mechanisms in IDH1 mutant glioma.
- Published in:
- Neuro-Oncology, 2022, v. 24, n. 6, p. 888, doi. 10.1093/neuonc/noab292
- By:
- Publication type:
- Article
Transcription factor GTF2B regulates AIP protein expression in growth hormone-secreting pituitary adenomas and influences tumor phenotypes.
- Published in:
- Neuro-Oncology, 2022, v. 24, n. 6, p. 925, doi. 10.1093/neuonc/noab291
- By:
- Publication type:
- Article
Neuronal exposure induces neurotransmitter signaling and synaptic mediators in tumors early in brain metastasis.
- Published in:
- Neuro-Oncology, 2022, v. 24, n. 6, p. 914, doi. 10.1093/neuonc/noab290
- By:
- Publication type:
- Article
Origins of biallelic inactivation of NF2 in neurofibromatosis type 2.
- Published in:
- Neuro-Oncology, 2022, v. 24, n. 6, p. 903, doi. 10.1093/neuonc/noab287
- By:
- Publication type:
- Article
Diffusion MRI is an early biomarker of overall survival benefit in IDH wild-type recurrent glioblastoma treated with immune checkpoint inhibitors.
- Published in:
- Neuro-Oncology, 2022, v. 24, n. 6, p. 1020, doi. 10.1093/neuonc/noab276
- By:
- Publication type:
- Article
Efficacy and safety of larotrectinib in TRK fusion-positive primary central nervous system tumors.
- Published in:
- Neuro-Oncology, 2022, v. 24, n. 6, p. 997, doi. 10.1093/neuonc/noab274
- By:
- Publication type:
- Article
Characterization and prognosis of temozolomide-induced aplastic anemia in patients with central nervous system malignancies.
- Published in:
- Neuro-Oncology, 2022, v. 24, n. 6, p. 964, doi. 10.1093/neuonc/noab240
- By:
- Publication type:
- Article